Format

Send to

Choose Destination
Blood. 2019 Aug 8;134(6):515-524. doi: 10.1182/blood.2019000785. Epub 2019 Jun 4.

How I treat primary cutaneous CD30+ lymphoproliferative disorders.

Author information

1
Division of Dermatology and.
2
Division of Hematology, Department of Medicine, University of Washington, Seattle, WA.

Abstract

The primary cutaneous CD30+ lymphoproliferative disorders are a family of extranodal lymphoid neoplasms that arise from mature postthymic T cells and localize to the skin. Current classification systems recognize lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma, and borderline cases. In the majority of patients, the prognosis of primary cutaneous CD30+ lymphoproliferative disorders is excellent; however, relapses are common, and complete cures are rare. Skin-directed and systemic therapies are used as monotherapy or in combination to achieve the best disease control and minimize overall toxicity. We discuss 3 distinct presentations of primary cutaneous CD30+ lymphoproliferative disorder and present recommendations for a multidisciplinary team approach to diagnosis, evaluation, and management of these conditions in keeping with existing consensus guidelines.

PMID:
31164331
DOI:
10.1182/blood.2019000785

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center